Clinical Research
BibTex RIS Cite

Year 2025, Volume: 7 Issue: 1, 75 - 80, 15.01.2025
https://doi.org/10.37990/medr.1496137

Abstract

References

  • Htay T, Soe K, Lopez-Perez A, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. Curr Cardiol Rep. 2019;21:45.
  • Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035-8.
  • Darabian S, Hormuz M, Latif MA, et al. The role of carotid intimal thickness testing and risk prediction in the development of coronary atherosclerosis. Curr Atheroscler Rep. 2013;15:306.
  • Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the american society of echocardiography carotid intima-media thickness task force endorsed by the society for vascular. J Am Soc Echocardiogr. 2008;21:93-190. Erratum in: J Am Soc Echocardiogr. 2008;21:376.
  • Olivier E, Soury E, Ruminy P, et al. Fetuin-B, a second member of the fetuin family in mammals. Biochem J. 2000;350:589-97.
  • Liu JX, Zhai YH, Geng FS, et al. Molecular characterization and expression pattern of fetuin-B in gibel carp (Carassius auratus gibelio). Biochem Genet. 2008;46:620-33.
  • Yang F, Schwartz Z, Swain LD, et al. Alpha2-HS-glycoprotein: Expression in chondrocytes and augmentation of alkaline phosphatase and phospholipase A2 activity. Bone. 1991;12:7-15.
  • Chen H, Srinivas PR, Cong LN, et al. Alpha2-Heremans Schmid glycoprotein inhibits insulin-stimulated Elk-1 phosphorylation, but not glucose transport, in rat adipose cells. Endocrinology. 1998;139:4147-54.
  • Ohnishi T, Nakamura O, Arakaki N, Daikuhara Y. Effect of phosphorylated rat fetuin on the growth of hepatocytes in primary culture in the presence of human hepatocyte-growth factor. Evidence that phosphorylated fetuin is a natural modulator of hepatocyte-growth factor. Eur J Biochem. 1997;243:753-61.
  • Wang H, Zhang M, Bianchi M, et al. Fetuin (α2-HS-glycoprotein) opsonizes cationic macrophage-deactivating molecules. Proc Natl Acad Sci U S A. 1998;95:14429-34.
  • Almarashda O, Abdi S, Yakout S, et al. Hepatokines fetuin-A and fetuin-B status in obese Saudi patient with diabetes mellitus type 2. Am J Transl Res. 2022;14:3292-302.
  • Peter A, Kovarova M, Staiger H, et al. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans. Am J Physiol Endocrinol Metab. 2018;314:E266-73.
  • American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41:S13-27.
  • Li L, Spranger L, Stobäus N, et al. Fetuin-B, a potential link of liver-adipose tissue cross talk during diet-induced weight loss–weight maintenance. Nutr Diabetes. 2021;11:31.
  • Wang D, Liu Y, Liu S, et al. Serum fetuin-B is positively associated with intrahepatic triglyceride content and increases the risk of insulin resistance in obese Chinese adults: A cross-sectional study. J Diabetes. 2018;10:581-8.
  • Pasmans K, Goossens GH, Groenhuijzen E, et al. Fetuin B in white adipose tissue induces inflammation and is associated with peripheral insulin resistance in mice and humans. Obesity. 2024;32:517-27.
  • Xia X, Xue S, Yang G, et al. Association of serum fetuin-B with insulin resistance and pre-diabetes in young Chinese women: evidence from a cross-sectional study and effect of liraglutide. PeerJ. 2021;9:e11869.
  • Qu H, Qiu Y, Wang Y, et al. Plasma fetuin-B concentrations are associated with insulin resistance and first-phase glucose-stimulated insulin secretion in individuals with different degrees of glucose tolerance. Diabetes Metab. 2018;44:488-92.
  • Zhu J, Wan X, Wang Y, et al. Serum fetuin B level increased in subjects of nonalcoholic fatty liver disease: a case-control study. Endocrine. 2017;56:208-11.
  • El-Ashmawy HM, Ahmed AM. Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes. Eur J Gastroenterol Hepatol. 2019;31:859-64.
  • Li Z, Lin M, Liu C, et al. Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: Association and path analyses. Cytokine. 2018;108:145-50.
  • Yakout SM, Hussein S, Al-Attas OS, et al. Hepatokines fetuin A and fetuin B status in women with/without gestational diabetes mellitus. Am J Transl Res. 2023;15:1291-9.
  • Li Z, He C, Liu Y, et al. Association of fetuin-b with subclinical atherosclerosis in obese chinese adults. J Atheroscler Thromb. 2020;27:418-28.
  • Hou J, Deng Q, Liu S, et al. Plasma proteome profiling of patients with in-stent restenosis by tandem mass tag-based quantitative proteomics approach. Front Cardiovasc Med. 2022;9:793405.

Relationship between Serum Fetuin-B Level and Metabolic Parameters in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Year 2025, Volume: 7 Issue: 1, 75 - 80, 15.01.2025
https://doi.org/10.37990/medr.1496137

Abstract

Aim: Fetuin-B, which is part of the fetuin family, has been demonstrated to be related with the emergence of insulin resistance. Here, we examined the relationship between metabolic parameters in treatment-naive patients with diabetes and fetuin B levels in serum.
Material and Method: Individuals aged 30-65 years old who were diagnosed with newly diagnosed diabetes mellitus, had no chronic disease history, and provided informed consent were enrolled in the study. The clinical parameters were examined.
Results: Forty recently diagnosed type 2 diabetic individuals and 43 controls were analyzed in this study. A significant difference was displayed for waist circumference, serum high-density lipoprotein, low-density lipoprotein, alanine transaminase, homeostatic model assessment for insulin resistance, high-sensitivity C-reactive protein, and carotid intima-media thickness (CIMT) between the two groups. The level of serum fetuin-B was determined to be statistically significantly reduced in diabetic patients compared to that in the serum of the controls. In the diabetic group, we showed a negative correlation between CIMT and fetuin-B (p=0.035).
Conclusion: Fetuin-B levels were considerably lower in recently diagnosed type 2 diabetics as equated with those in the control group who had normal glucose levels. Additionally, an inverse association between CIMT and fetuin-B levels among individuals with recently diagnosed type 2 diabetes mellitus.

Ethical Statement

Local ethics approval was obtained upon decision of 18.08.2015 No: 2 from the Non-Interventional Clinical Research Ethics Committee of Izmir Bozyaka Training and Research Hospital.

References

  • Htay T, Soe K, Lopez-Perez A, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. Curr Cardiol Rep. 2019;21:45.
  • Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035-8.
  • Darabian S, Hormuz M, Latif MA, et al. The role of carotid intimal thickness testing and risk prediction in the development of coronary atherosclerosis. Curr Atheroscler Rep. 2013;15:306.
  • Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the american society of echocardiography carotid intima-media thickness task force endorsed by the society for vascular. J Am Soc Echocardiogr. 2008;21:93-190. Erratum in: J Am Soc Echocardiogr. 2008;21:376.
  • Olivier E, Soury E, Ruminy P, et al. Fetuin-B, a second member of the fetuin family in mammals. Biochem J. 2000;350:589-97.
  • Liu JX, Zhai YH, Geng FS, et al. Molecular characterization and expression pattern of fetuin-B in gibel carp (Carassius auratus gibelio). Biochem Genet. 2008;46:620-33.
  • Yang F, Schwartz Z, Swain LD, et al. Alpha2-HS-glycoprotein: Expression in chondrocytes and augmentation of alkaline phosphatase and phospholipase A2 activity. Bone. 1991;12:7-15.
  • Chen H, Srinivas PR, Cong LN, et al. Alpha2-Heremans Schmid glycoprotein inhibits insulin-stimulated Elk-1 phosphorylation, but not glucose transport, in rat adipose cells. Endocrinology. 1998;139:4147-54.
  • Ohnishi T, Nakamura O, Arakaki N, Daikuhara Y. Effect of phosphorylated rat fetuin on the growth of hepatocytes in primary culture in the presence of human hepatocyte-growth factor. Evidence that phosphorylated fetuin is a natural modulator of hepatocyte-growth factor. Eur J Biochem. 1997;243:753-61.
  • Wang H, Zhang M, Bianchi M, et al. Fetuin (α2-HS-glycoprotein) opsonizes cationic macrophage-deactivating molecules. Proc Natl Acad Sci U S A. 1998;95:14429-34.
  • Almarashda O, Abdi S, Yakout S, et al. Hepatokines fetuin-A and fetuin-B status in obese Saudi patient with diabetes mellitus type 2. Am J Transl Res. 2022;14:3292-302.
  • Peter A, Kovarova M, Staiger H, et al. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans. Am J Physiol Endocrinol Metab. 2018;314:E266-73.
  • American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41:S13-27.
  • Li L, Spranger L, Stobäus N, et al. Fetuin-B, a potential link of liver-adipose tissue cross talk during diet-induced weight loss–weight maintenance. Nutr Diabetes. 2021;11:31.
  • Wang D, Liu Y, Liu S, et al. Serum fetuin-B is positively associated with intrahepatic triglyceride content and increases the risk of insulin resistance in obese Chinese adults: A cross-sectional study. J Diabetes. 2018;10:581-8.
  • Pasmans K, Goossens GH, Groenhuijzen E, et al. Fetuin B in white adipose tissue induces inflammation and is associated with peripheral insulin resistance in mice and humans. Obesity. 2024;32:517-27.
  • Xia X, Xue S, Yang G, et al. Association of serum fetuin-B with insulin resistance and pre-diabetes in young Chinese women: evidence from a cross-sectional study and effect of liraglutide. PeerJ. 2021;9:e11869.
  • Qu H, Qiu Y, Wang Y, et al. Plasma fetuin-B concentrations are associated with insulin resistance and first-phase glucose-stimulated insulin secretion in individuals with different degrees of glucose tolerance. Diabetes Metab. 2018;44:488-92.
  • Zhu J, Wan X, Wang Y, et al. Serum fetuin B level increased in subjects of nonalcoholic fatty liver disease: a case-control study. Endocrine. 2017;56:208-11.
  • El-Ashmawy HM, Ahmed AM. Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes. Eur J Gastroenterol Hepatol. 2019;31:859-64.
  • Li Z, Lin M, Liu C, et al. Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: Association and path analyses. Cytokine. 2018;108:145-50.
  • Yakout SM, Hussein S, Al-Attas OS, et al. Hepatokines fetuin A and fetuin B status in women with/without gestational diabetes mellitus. Am J Transl Res. 2023;15:1291-9.
  • Li Z, He C, Liu Y, et al. Association of fetuin-b with subclinical atherosclerosis in obese chinese adults. J Atheroscler Thromb. 2020;27:418-28.
  • Hou J, Deng Q, Liu S, et al. Plasma proteome profiling of patients with in-stent restenosis by tandem mass tag-based quantitative proteomics approach. Front Cardiovasc Med. 2022;9:793405.
There are 24 citations in total.

Details

Primary Language English
Subjects Endocrinology
Journal Section Original Articles
Authors

Canan Karan 0000-0002-1293-2046

Mehmet Çalan 0000-0002-5614-0710

Arif Yüksel 0000-0002-8568-5787

Oktay Bilgir 0000-0001-9579-0583

Giray Bozkaya 0000-0002-5756-5796

Emre Gezer 0000-0002-5340-6106

Publication Date January 15, 2025
Submission Date June 5, 2024
Acceptance Date September 9, 2024
Published in Issue Year 2025 Volume: 7 Issue: 1

Cite

AMA Karan C, Çalan M, Yüksel A, Bilgir O, Bozkaya G, Gezer E. Relationship between Serum Fetuin-B Level and Metabolic Parameters in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. Med Records. January 2025;7(1):75-80. doi:10.37990/medr.1496137

Chief Editors
MD, Professor. Berkant Özpolat
Department of Thoracic Surgery, Ufuk University, Dr. Rıdvan Ege Hospital, Ankara, Türkiye

Editors
MD, Professor. Sercan Okutucu
Department of Cardiology, Ankara Lokman Hekim University, Ankara, Türkiye
MD, Assoc. Prof. Süleyman Cebeci
Department of Ear, Nose and Throat Diseases, Gazi University Faculty of Medicine, Ankara, Türkiye

Field Editors
MD, Assoc. Prof. Doğan Öztürk
Department of General Surgery, Manisa Özel Sarıkız Hospital, Manisa, Türkiye
MD, Assoc. Prof. Birsen Doğanay
Department of Cardiology, Ankara Bilkent City Hospital, Ankara, Türkiye
MD, Assoc. Prof. Sonay Aydın
Department of Radiology, Erzincan Binali Yıldırım University Faculty of Medicine, Erzincan, Türkiye

Language Editors
PhD, Dr. Evin Mise
Department of Work Psychology, Ankara University, Ayaş Vocational School, Ankara, Türkiye
Dr. Dt. Çise Nazım
Department of Periodontology, Dr. Burhan Nalbantoğlu State Hospital, Lefkoşa, North Cyprus

Statistics Editor
PhD, Dr. Nurbanu Bursa
Department of Statistics, Hacettepe University, Faculty of Science, Ankara, Türkiye

Scientific Publication Coordinator
Kübra Toğlu
argistyayincilik@gmail.com

Franchise Owner
Argist Yayıncılık
argistyayincilik@gmail.com

Publisher: Argist Yayıncılık
E-mail: argistyayincilik@gmail.com

Phone: 0 533 320 32 09/0 312 979 02 35

Address: Kızılırmak Mahallesi Dumlupınar Bulvarı No:3 C-1 160 Çankaya/Ankara, Türkiye
Web: www.argistyayin.com.tr